JWCTF (JW (Cayman) Therapeutics Co) Long-Term Debt: $2.56 Mil (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
28 GF Score
Price $0.20
GF Value $0.47
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Long-Term Debt?

JW (Cayman) Therapeutics Co JWCTF -4.38% 28 Long-Term Debt is $2.56 Mil as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.47 (Possible Value Trap). The stock has 3 warning signs investors should review.

JW (Cayman) Therapeutics Co's Long-Term Debt for the quarter that ended in Dec. 2025 was $2.56 Mil.

JW (Cayman) Therapeutics Co's quarterly Long-Term Debt increased from Dec. 2024 ($2.68 Mil) to Jun. 2025 ($2.69 Mil) but then declined from Jun. 2025 ($2.69 Mil) to Dec. 2025 ($2.56 Mil).

JW (Cayman) Therapeutics Co's annual Long-Term Debt declined from Dec. 2023 ($22.06 Mil) to Dec. 2024 ($2.68 Mil) and declined from Dec. 2024 ($2.68 Mil) to Dec. 2025 ($2.56 Mil).

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

JW (Cayman) Therapeutics Co Long-Term Debt Related Terms

JW (Cayman) Therapeutics Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Long-Term Debt Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 14.92 13.27 22.06 2.68 2.56

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.06 19.45 2.68 2.69 2.56
JWCTF
28GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $2.56 Mil mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Long-Term Debt of $2.56 Mil as of Dec. 2025.
Is JW (Cayman) Therapeutics Co's Long-Term Debt too high?
JW (Cayman) Therapeutics Co's current Long-Term Debt is $2.56 Mil. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Long-Term Debt compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's Long-Term Debt of $2.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. JW (Cayman) Therapeutics Co's current Long-Term Debt is $2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.47, compared to a current price of $0.20 — trading 57% below its estimated fair value. The current Long-Term Debt is $2.56 Mil. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Long-Term Debt is $2.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.20 is trading 57% below its estimated GF Value™ of $0.47. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Long-Term Debt: $2.56 Mil
  • GF Value™: $0.47 vs. price of $0.20 (57% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score

Get the complete analysis for JWCTF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.47
GF Value